Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $127000.0.

  • Neurogene's Capital Expenditures fell 2865.17% to $127000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 3959.09%. This contributed to the annual value of $808000.0 for FY2024, which is 15171.34% up from last year.
  • As of Q3 2025, Neurogene's Capital Expenditures stood at $127000.0, which was down 2865.17% from $148000.0 recorded in Q2 2025.
  • Neurogene's Capital Expenditures' 5-year high stood at $780000.0 during Q1 2025, with a 5-year trough of $29000.0 in Q1 2023.
  • For the 3-year period, Neurogene's Capital Expenditures averaged around $198545.5, with its median value being $128000.0 (2023).
  • Data for Neurogene's Capital Expenditures shows a peak YoY increase of 45319.15% (in 2025) and a maximum YoY decrease of 6145.83% (in 2025) over the last 5 years.
  • Over the past 3 years, Neurogene's Capital Expenditures (Quarter) stood at $128000.0 in 2023, then decreased by 17.97% to $105000.0 in 2024, then rose by 20.95% to $127000.0 in 2025.
  • Its Capital Expenditures stands at $127000.0 for Q3 2025, versus $148000.0 for Q2 2025 and $780000.0 for Q1 2025.